Do you want to read an article? Please log in or register.
Preclinical stages of Crohn's disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials
Further Publications
Related content
Inflammatory Bowel Disease
Longitudinal Profiles of Fecal Calprotectin and C-Reactive Protein in Relation to Outcomes in Crohn's Disease Patients on Infliximab
J Crohns Colitis
Magro F, Domingues B, Estevinho MM, Patita M, Arroja B, Lago P, Rosa I, de Sousa HT, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, Portela F, Correia L, Fernandes S, Dias CC, Dias S, Peyrin-Biroulet L, Danese S, Santiago M, GEDII
doi: 10.1093/ecco-jcc/jjaf120
Inflammatory Bowel Disease
Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial
Lancet Gastroenterol Hepatol
Pigneur B, Martinez-Vinson C, Bourmaud A, Dabadie A, Duclaux-Loras R, Hugot JP, Roman C, Dumant C, Spyckerelle C, Guinard-Samuel V, Willot S, Dupont C, Breton A, Caron N, Chaillou E, Rebouissoux L, Bertrand V, Triolo V, Pages J, Djeddi D, Bonneton M, Uhlen S, Catteau N, Coopman S, Lepage P, Viala J, Ruemmele FM
doi: 10.1016/S2468-1253(25)00262-6
Inflammatory Bowel Disease
Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn's Disease: Opportunities and Challenges
Inflamm Bowel Dis
Jairath V, Adsul S, Allocca M, Danese S, Dubinsky MC, de Oliveira MF, Ma C, Kucharzik T, Novak KL, Panaccione R, Bautista IR, Sands BE, Taylor SA, Wilkens R, Maaser C
doi: 10.1093/ibd/izaf196
Inflammatory Bowel Disease
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)
J Crohns Colitis
Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB
doi: 10.1093/ecco-jcc/jjaf060
Inflammatory Bowel Disease
Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Trial
Clin Gastroenterol Hepatol
Jairath V, D'Haens G, Sands BE, Travis S, Chaparro M, Peyrin-Biroulet L, Chen MH, Dubinsky M, Ferrante M, Schreiber S, McGinnis K, Vadhariya A, Appelmans S, Lin Z, Yu G, Protic M, Moses R, Ghosh S
doi: 10.1016/j.cgh.2025.07.003
Inflammatory Bowel Disease
Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn's Disease: A Post Hoc Analysis of the SEAVUE Trial
Inflamm Bowel Dis
Ahuja D, Anvari S, Wong ECL, Dulai P, Marshall JK, Jairath V, Reinisch W, Narula N
doi: 10.1093/ibd/izaf137
RECOMMENDED
ColonoscopyInflammatory Bowel Disease
The EXTENT Study: Results from an International Expert Delphi Consensus to define Ultrasonographic Parameters for Measuring Bowel Damage in Crohn's Disease
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Clin Gastroenterol Hepatol
Palmela C, Torres J, Frias-Gomes C, Allocca M, Buisson A, Colombel JF, Novak K, Rimola J, Albshesh A, Bonifacio C, Krugliak Cleveland N, De Voogd F, Dolinger M, Furfaro F, Jauregui-Amezaga A, Karakan T, Kellar A, Kralj D, Lu C, Pruijt M, Rieder F, Roager Madsen G, Vizhi Nagarajan K, Sagami S, Scharitzer M, Stoker J, Taylor SA, Christian Tews H, Vanslembrouck R, Vaughan R, Wilkens R, Maaser C, Verstockt B
doi: 10.1016/j.cgh.2025.07.024
Inflammatory Bowel Disease
IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn's Disease: A Meta-analysis of Randomized Controlled Trials
Am J Gastroenterol
Dziegielewski C, Yuan Y, Ma C, Boland BS, Chang JT, Syal G, Vuyyuru SK, Peyrin-Biroulet L, Jairath V, Singh S
doi: 10.14309/ajg.0000000000003406
Inflammatory Bowel Disease
Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis
J Crohns Colitis
D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S
doi: 10.1093/ecco-jcc/jjaf080